	US 12,146,159 B2
	Methods for obtaining regulatory t cells and uses thereof
Carole Guillonneau, Nantes (FR); Ignacio Anegon, Nantes (FR); and Severine Bezie, Nantes (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); NANTES UNIVERSITE, Nantes (FR); and CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, Nantes (FR)
Filed by INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); UNIVERSITE DE NANTES, Nantes (FR); and CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, Nantes (FR)
Filed on Jun. 11, 2020, as Appl. No. 16/899,142.
Application 16/899,142 is a division of application No. 15/740,997, granted, now 10,724,001, previously published as PCT/EP2016/065572, filed on Jul. 1, 2016.
Claims priority of application No. 15306092 (EP), filed on Jul. 3, 2015.
Prior Publication US 2020/0308543 A1, Oct. 1, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 35/15 (2015.01); A61K 35/17 (2015.01); A61P 37/06 (2006.01); C12N 5/0786 (2010.01)

CPC C12N 5/0637 (2013.01) [A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61P 37/06 (2018.01); C12N 5/0645 (2013.01); C12N 2501/2334 (2013.01); C12N 2501/599 (2013.01); C12N 2502/1157 (2013.01)]

12 Claims

1. A method for treating an immune and/or inflammatory disease or condition in a subject, comprising obtaining a population of human CD8+ CD45RC^lowTreg cells by: (a) culturing a population of human monocytes in presence of interleukin-34 (IL-34) polypeptide in order to obtain a population of immunosuppressive macrophages; (b) co-culturing a population of human peripheral blood mononuclear cells (PBMCs) and the population of immunosuppressive macrophages obtained at step (a) to obtain a population of human CD8+ CD45RC^lowTreg cells; and (c) optionally isolating the human CD8+ CD45RC^lowTreg cells from the population obtained at step (b); and administering said population or said isolated population of human CD8+ CD45RC^lowTreg cells to the subject, wherein the immune and/or inflammatory disease or condition is selected from the group consisting of an autoimmune disease, graft rejection and GVHD.